
Ori®Ab
Antibody discovery technology platform

Ori®CAR
CAR-T technology platform with high memory and high vitality
OriCell Therapeutics gives full play to independently-developed technology platforms and sets out to break through the efficacy and cost bottlenecks in CAR T-cell therapy for solid tumors:
Target screening: The Ori®Ab platform not only offers high-quality and highly synergistic targets for the CAR-T products but also screens out the appropriate ones to develop candidate antibody drugs. These products are authorized and licensed or are developed in a collaborative manner to create values for the company;
Innovative structure: The Ori®CAR platform with an innovative structure can expand the memory T-cells at a rate that is several-fold higher so that the cell products can effectively resist the immunosuppressive tumor microenvironment;